These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 1796409)

  • 1. Effects on coagulation and fibrinolysis of desmopressin in patients undergoing total hip replacement.
    Flordal PA; Ljungström KG; Svensson J; Ekman B; Neander G
    Thromb Haemost; 1991 Dec; 66(6):652-6. PubMed ID: 1796409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of desmopressin and dextran on coagulation and fibrinolysis in healthy volunteers.
    Flordal PA; Svensson J; Ljungström KG
    Thromb Res; 1991 Jun; 62(5):355-64. PubMed ID: 1716790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1-Desamino-8-D-arginine vasopressin (DDAVP) in patients with congenital nephrogenic diabetes insipidus.
    Brink HS; Derkx FH; Boomsma F; Brommer EJ; Schalekamp MA
    Neth J Med; 1993 Aug; 43(1-2):5-12. PubMed ID: 8232694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
    Siegbahn A; Ruusuvaara L
    Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Desmopressin (DDAVP) for treatment of disorders of hemostasis.
    Mannucci PM
    Prog Hemost Thromb; 1986; 8():19-45. PubMed ID: 3104987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of desmopressin acetate (DDAVP) as a test of the fibrinolytic capacity of patients--analysis of responders and non-responders.
    Brommer EJ; Barrett-Bergshoeff MM; Allen RA; Schicht I; Bertina RM; Schalekamp MA
    Thromb Haemost; 1982 Oct; 48(2):156-61. PubMed ID: 6817444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DDAVP infusion in haemophilia A carriers: different behaviour of plasma factor VIII and von Willebrand factor.
    Casonato A; Dannhauser D; Pontara E; Bertomoro A; Orazi B; Santarossa L; Zerbinati P; Girolami A
    Blood Coagul Fibrinolysis; 1996 Jul; 7(5):549-53. PubMed ID: 8874865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
    Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z
    Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Desmopressin has no beneficial effect on excessive postoperative bleeding or blood product requirements associated with cardiopulmonary bypass.
    de Prost D; Barbier-Boehm G; Hazebroucq J; Ibrahim H; Bielsky MC; Hvass U; Lacombe C; Français JL; Desmonts JM
    Thromb Haemost; 1992 Aug; 68(2):106-10. PubMed ID: 1412152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
    Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
    Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood fibrinolysis and the response to desmopressin in glomerulonephritis.
    Brommer EJ; Van den Wall Bake AW; Dooijewaard G; van Loon BJ; Emeis JJ; Weening JJ
    Thromb Haemost; 1994 Jan; 71(1):19-25. PubMed ID: 8165642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with desmopressin acetate to reduce blood loss after cardiac surgery. A double-blind randomized trial.
    Salzman EW; Weinstein MJ; Weintraub RM; Ware JA; Thurer RL; Robertson L; Donovan A; Gaffney T; Bertele V; Troll J
    N Engl J Med; 1986 May; 314(22):1402-6. PubMed ID: 3517650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of desamino-D-arginine vasopressin (DDAVP) and naloxone infusions on factor VIII and possible endothelial cell (EC) related activities.
    Moffat EH; Giddings JC; Bloom AL
    Br J Haematol; 1984 Aug; 57(4):651-62. PubMed ID: 6430337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibrinolytic and haemostatic responses to desamino-D-arginine vasopressin (DDAVP) administered by intravenous and subcutaneous routes in healthy subjects.
    MacGregor IR; Roberts EM; Prowse CV; Broomhead AF; Ozolins M; Litka P
    Thromb Haemost; 1988 Feb; 59(1):34-9. PubMed ID: 3129807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heparin, DDAVP and the bleeding time.
    Schulman S; Johnsson H
    Thromb Haemost; 1991 Mar; 65(3):242-4. PubMed ID: 2048049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acquired von Willebrand disease--hemostatic management of major orthopedic surgery with high-dose immunoglobulin, desmopressin, and continuous factor concentrate infusion.
    Frank RD; Kunz D; Wirtz DC
    Am J Hematol; 2002 May; 70(1):64-71. PubMed ID: 11994985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of desmopressin effects on haemostasis in children with congenital bleeding disorders.
    Hanebutt FL; Rolf N; Loesel A; Kuhlisch E; Siegert G; Knoefler R
    Haemophilia; 2008 May; 14(3):524-30. PubMed ID: 18284449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Laboratory response to intranasal desmopressin in women with menorrhagia and platelet dysfunction.
    Rose SS; Faiz A; Miller CH; Saidi P; Philipp CS
    Haemophilia; 2008 May; 14(3):571-8. PubMed ID: 18312366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of inherited von Willebrand disease in 2006.
    Federici AB
    Semin Thromb Hemost; 2006 Sep; 32(6):616-20. PubMed ID: 16977571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemostatic and fibrinolytic response to nasal desmopressin in hemodialysis patients.
    Ulusoy S; Ovali E; Aydin F; Erem C; Ozdemir F; Kaynar K
    Med Princ Pract; 2004; 13(6):340-5. PubMed ID: 15467309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.